‎ Lamotrigine Augmentation versus Placebo in Serotonin ‎Reuptake Inhibitors-‎Resistant Obsessive-Compulsive Disorder: ‎A Randomized Controlled Trial


Objective: Serotonin reuptake inhibitors are frequently used in first-line treatments for patients ‎with obsessive-compulsive disorder. Nevertheless, many of these patients do not ‎respond well to initial therapy. The hypothesis of glutamatergic dysfunction in specific ‎brain regions has been proposed in the pathophysiology of obsessive-compulsive ‎disorder. This study was designed to evaluate the possible efficacy of lamotrigine, a ‎glutamatergic agent in Serotonin reuptake inhibitors-resistant patients with obsessive-‎compulsive disorder.‎
Method: This study was a 12-week, double blind, randomized, placebo-controlled trial of ‎adjunctive fixed-doses of lamotrigine (100 mg) to Serotonin reuptake inhibitors therapy ‎in obsessive-compulsive disorder. Eligible subjects who had a total Y-BOCS of 21 or ‎above were randomly assigned to receive adjunctive treatment with either lamotrigine ‎‎(n = 26), or placebo (n = 27). Response to lamotrigine was defined as clinical ‎improvement (>25% decrease in the total Y-BOCS score), which was administered at ‎weeks 0, 8 and 12.‎
Results: At the endpoint (week 12), significant differences were observed in obsession, ‎compulsion, and total Y-BOCS scores comparing lamotrigine to placebo (P = 0.01, ‎‎0.005 and 0.007 respectively). The mean reduction in obsession, compulsion and total ‎scores in lamotrigine group was about 4.15, 4.50 and 8.73, respectively. Similarly, the ‎mean reductions in the placebo group were 2.52, 2.56 and 5.07. Effect sizes for efficacy ‎measures were calculated by Cohen’s d, and it was calculated as 0.54 for the total ‎YBOCS.‎
Conclusion: Our findings provide evidence that this augmentation is well tolerated and may be an ‎effective strategy for patients with refractory obsessive-compulsive disorder.‎‎

‎1.‎ Subramaniam M, Abdin E, Vaingankar JA, ‎Chong SA. Obsessive--compulsive ‎disorder: prevalence, correlates, help-‎seeking and quality of life in a multiracial ‎Asian population. Soc Psychiatry Psychiatr ‎Epidemiol 2012; 47: 2035-2043.‎

‎2.‎ Subramaniam M, Soh P, Vaingankar JA, ‎Picco L, Chong SA. Quality of life in ‎obsessive-compulsive disorder: impact of ‎the disorder and of treatment. CNS Drugs ‎‎2013; 27: 367-383.‎

‎3.‎ ‎Seibell PJ, Hollander E. Management of ‎obsessive-compulsive ‎Disorder. ‎F1000Prime Rep. 2014; ‎‎1: 6: 68-‎‎74.‎

‎4.‎ Fornaro M. Switching from serotonin ‎reuptake inhibitors to agomelatine ‎in ‎patients with ‎refractory obsessive-‎compulsive disorder: a 3 month follow-up ‎case series. ‎Ann Gen Psychiatry 2011; ‎‎28: ‎‎10.5‎

‎5.‎ Bruno A, Mico U, Pandolfo G, Mallamace ‎D, Abenavoli E, Di Nardo F, et al. ‎Lamotrigine augmentation of serotonin ‎reuptake inhibitors in treatment-resistant ‎obsessive-compulsive disorder: a double-‎blind, placebo-controlled study. J ‎Psychopharmacol 2012; 26: 1456-1462.‎

‎6.‎ Dold M, Aigner M, Lanzenberger R, ‎Kasper S. Antipsychotic augmentation of ‎serotonin reuptake inhibitors in treatment-‎resistant obsessive-compulsive disorder: a ‎meta-analysis of double-blind, ‎randomized, placebo-controlled trials. Int J ‎Neuropsychopharmacol 2013; 16: 557-‎‎574.‎

‎7.‎ Abudy A, Juven-Wetzler A, Zohar J. ‎Pharmacological management of ‎treatment-resistant obsessive-compulsive ‎disorder. CNS Drugs 2011; 25: 585-596.‎

‎8.‎ Bandelow B. The medical treatment of ‎obsessive-compulsive disorder and ‎anxiety. CNS Spectr 2008; 13: 37-46.‎

‎9.‎ Bloch MH, Landeros-Weisenberger A, ‎Kelmendi B, Coric V, Bracken MB, ‎Leckman JF. A systematic review: ‎antipsychotic augmentation with treatment ‎refractory obsessive-compulsive disorder. ‎Mol Psychiatry 2006; 11: 622-632.‎

‎10.‎ Coric V, Taskiran S, Pittenger C, Wasylink ‎S, Mathalon DH, Valentine G, et al. ‎Riluzole augmentation in treatment-‎resistant obsessive-compulsive disorder: ‎an open-label trial. Biol Psychiatry 2005; ‎‎58: 424-428.‎

‎11.‎ Naaijen J, Lythgoe DJ, Amiri H, Buitelaar ‎JK, Glennon JC. Fronto-striatal ‎glutamatergic compounds in compulsive ‎and impulsive syndromes: a review of ‎magnetic resonance spectroscopy studies. ‎Neurosci Biobehav Rev 2015; 52: 74-88.‎

‎12.‎ Wu K, Hanna GL, Rosenberg DR, Arnold ‎PD. The role of glutamate signaling in the ‎pathogenesis and treatment of obsessive-‎compulsive disorder. Pharmacol Biochem ‎Behav 2012; 100: 726-735.‎

‎13.‎ Bhattacharyya S, Chakraborty K. ‎Glutamatergic dysfunction--newer targets ‎for anti-obsessional drugs. Recent Pat ‎CNS Drug Discov 2007; 2: 47-55.‎

‎14.‎ Pittenger C, Krystal JH, Coric V. ‎Glutamate-modulating drugs as novel ‎pharmacotherapeutic agents in the ‎treatment of obsessive-compulsive ‎disorder. NeuroRx 2006; 3: 69-81.‎

‎15.‎ Pittenger C, Bloch MH, Williams K. ‎Glutamate abnormalities in obsessive ‎compulsive disorder: neurobiology, ‎pathophysiology, and treatment. ‎Pharmacol Ther 2011; 132: 314-332.‎

‎16.‎ Goodman WK, Grice DE, Lapidus KA, ‎Coffey BJ. Obsessive-compulsive ‎disorder. Psychiatric Clinics of North ‎America 2014; 37: 257-267.‎

‎17.‎ Nakamae T. [Novel treatment strategies ‎for refractory patients with obsessive-‎compulsive disorder]. Seishin shinkeigaku ‎zasshi = Psychiatria et neurologia ‎Japonica 2013; 115: 997-1003.‎

‎18.‎ Grados MA, Specht MW, Sung HM, ‎Fortune D. Glutamate drugs and ‎pharmacogenetics of OCD: a pathway-‎based exploratory approach. Expert Opin ‎Drug Discov 2013; 8: 1515-1527.‎

‎19.‎ ‎Fineberg NA, Brown A, Reghunandanan ‎S, Pampaloni I. Evidence-‎‎basedpharmacotherapy of ‎obsessive-‎compulsivedisorder.Int J ‎Neuropsychopharmacol ‎‎2012; 15: 1173-‎‎1191.‎

‎20.‎ Grant P, Lougee L, Hirschtritt M, Swedo ‎SE. An open-label trial of riluzole, a ‎glutamate antagonist, in children with ‎treatment-resistant obsessive-compulsive ‎disorder. J Child Adolesc ‎Psychopharmacol 2007; 17: 761-767.‎

‎21.‎ Grant PJ, Joseph LA, Farmer CA, ‎Luckenbaugh DA, Lougee LC, Zarate CA, ‎Jr., et al. 12-week, placebo-controlled trial ‎of add-on riluzole in the treatment of ‎childhood-onset obsessive-compulsive ‎disorder. Neuropsychopharmacology ‎‎2014; 39: 1453-1459.‎

‎22.‎ Bakhla AK, Verma V, Soren S, Sarkhel S , ‎Chaudhury S. An open-label trial of ‎memantine in treatment-resistant ‎obsessive-compulsive disorder. Ind ‎Psychiatry J 2013; 22: 149-152.‎

‎23.‎ Hosenbocus S, Chahal R. Memantine: a ‎review of possible uses in child and ‎adolescent psychiatry. J Can Acad Child ‎Adolesc Psychiatry 2013; 22: 166-171.‎

‎24.‎ Haghighi M, Jahangard L, Mohammad-‎Beigi H, Bajoghli H, Hafezian H, Rahimi A, ‎et al. In a double-blind, randomized and ‎placebo-controlled trial, adjuvant ‎memantine improved symptoms in ‎inpatients suffering from refractory ‎obsessive-compulsive disorders (OCD). ‎Psychopharmacology (Berl) 2013; 228: ‎‎633-640.‎

‎25.‎ Ghaleiha A, Entezari N, Modabbernia A, ‎Najand B, Askari N, et al. Memantine add-‎on in moderate to severe obsessive-‎compulsive disorder: randomized double-‎blind placebo-controlled study. J Psychiatr ‎Res. 2013; 47: 175-180.‎

‎26.‎ Stewart SE, Jenike EA, Hezel DM, Stack ‎DE, Dodman NH, Shuster L, et al. A ‎single-blinded case-control study of ‎memantine in severe obsessive-‎compulsive disorder. J Clin ‎Psychopharmacol 2010; 30: 34-39.‎

‎27.‎ Egashira N, Shirakawa A, Abe M, Niki T, ‎Mishima K, Iwasaki K, et al. N-acetyl-L-‎cysteine inhibits marble-burying behavior ‎in mice. J Pharmacol Sci 2012; 119: 97-‎‎101.‎

‎28.‎ Xia J, Du Y, Han J, Liu G , Wang X. D-‎cycloserine augmentation in behavioral ‎therapy for obsessive-compulsive ‎disorder: a meta-analysis. Drug Des Devel ‎Ther 2015; 9: 2101-2117.‎

‎29.‎ Chasson GS, Buhlmann U, Tolin DF, Rao ‎SR, Reese HE and Rowley T, et al. Need ‎for speed: evaluating slopes of OCD ‎recovery in behavior therapy enhanced ‎with d-cycloserine. Behav Res Ther 2010; ‎‎48: 675-679.‎

‎30.‎ Berlin HA, Koran LM, Jenike MA, Shapira ‎NA, Chaplin W, Pallanti S, et al. Double-‎blind, placebo-controlled trial of ‎topiramate augmentation in treatment-‎resistant obsessive-compulsive disorder. J ‎Clin Psychiatry 2011; 72: 716-721.‎

‎31.‎ Reid JG, Gitlin MJ, Altshuler LL. ‎Lamotrigine in psychiatric disorders. J ‎Clin ‎Psychiatry. 2013; 74:‎‏ ‏‎675-‎‎684‎‏.‏

‎32.‎ Italiano D, Perucca E. Clinical ‎pharmacokinetics of new-generation ‎antiepileptic drugs at the extremes of age: ‎an update. Clin Pharmacokinet 2013; 52: ‎‎627-645.‎

‎33.‎ Kumar TC, Khanna S. Lamotrigine ‎augmentation of serotonin re-uptake ‎inhibitors in obsessive-compulsive ‎disorder. Aust N Z J Psychiatry 2000; 34: ‎‎527-528.‎

‎34.‎ Arrojo-Romero M, Tajes Alonso M , de ‎Leon J. Lamotrigine augmentation of ‎serotonin reuptake inhibitors in severe and ‎long-term treatment-resistant obsessive-‎compulsive disorder. Case Rep Psychiatry ‎‎2013; 2013: 1245-1249.‎

‎35.‎ ‎ Goodman WK, Price LH, Rasmussen SA, ‎Mazure C, Delgado P, et al. The Yale-‎Brown ‎Obsessive ‎Compulsive Scale II. ‎Validity Arch Gen Psychiatry 1989; ‎‎46:1006-1011.‎

‎36.‎ ‎Poyurovsky M, Glick I, Koran LM. ‎Lamotrigine augmentation in ‎schizophrenia and ‎schizoaffective ‎patients ‎with obsessive-compulsive symptoms. J ‎Psychopharmacol 2010; ‎‎24: 861-866.‎

‎37.‎ ‎Zavodnick AD, Ali R.Lamotrigine in the ‎treatment of unipolar depression with ‎and ‎without ‎comorbidities: a literature ‎review. Psychiatr Q 2012; 83: 371-383.‎

‎38.‎ ‎Afshar H, Akuchekian SH, ahaky B, ‎Zarean E. Topiramate augmentation ‎in ‎refractory obsessive-‎compulsive ‎disorder: A randomized, double-blind, ‎placebo-‎controlled trial. J Res Med ‎Sci2014; 19: 976–‎‎981.‎

‎39.‎ ‎Damien F, Ted K , Franklin M, Fabrizio B. ‎Placebo Effects: Biological, Clinical and ‎Ethical ‎Advances. Lancet 2010; 375: 686-‎‎695.‎

‎40.‎ Wang XQ, Xiong J, Xu WH, Yu SY, Huang ‎XS, Zhang JT, et al. Risk of a lamotrigine-‎related skin rash: current meta-analysis ‎and postmarketing cohort analysis. ‎Seizure 2015; 25: 52-61.‎

‎41.‎ Pallanti S, Grassi G. Pharmacologic ‎treatment of obsessive-compulsive ‎disorder comorbidity‏. ‏Expert Opin ‎Pharmacother 2014; 15: 2543-2552.‎

‎42.‎ ‎Woody E, Szechtman H. Motivation, time ‎course, and heterogeneity in ‎obsessive-‎compulsive ‎disorder. Psychological ‎Review 2005; 112: 658-661.‎

‎43.‎ Watson HJ, Rees CS. Meta-analysis of ‎randomized, controlled treatment trials for ‎pediatric obsessive-compulsive disorder. J ‎Child Psychol Psychiatry 2008; 49: 489-‎‎498.‎

‎44.‎ Bandelow B. The medical treatment of ‎obsessive-compulsive disorder and ‎anxiety. CNS Spectr 2008; 13: 37-46.‎

‎45.‎ Amerio A, Stubbs B, Odone A, Tonna M, ‎Marchesi C , Ghaemi SN. The prevalence and ‎predictors of comorbid bipolar disorder and ‎obsessive-compulsive disorder: A systematic ‎review and meta-analysis. J Affect Disord ‎‎2015; 186: 99-109.‎

‎46.‎ Geddes JR, Calabrese JR, Goodwin GM. ‎Lamotrigine for treatment of bipolar ‎depression: independent meta-analysis ‎and meta-regression of individual patient ‎data from five randomised trials. Br J ‎Psychiatry 2009; 194: 4-9.‎

‎47.‎ Jeong JH, Lee JG, Kim MD, Sohn I, Shim ‎SH, Wang HR, et al. Korean Medication ‎Algorithm for Bipolar Disorder 2014: ‎comparisons with other treatment ‎guidelines. Neuropsychiatr Dis Treat 2015; ‎‎11: 1561-1571.‎

‎48.‎ Wang HR, Woo YS, Bahk WM. ‎Anticonvulsants to treat post-traumatic ‎stress disorder. Hum Psychopharmacol ‎‎2014; 29: 427-433.‎

IssueVol 11 No 2 (2016) QRcode
Drug Augmentation Lamotrigine ‎Obsessive-Compulsive Disorder ‎Serotonin Reuptake ‎Inhibitors ‎Treatment-Resistant

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Khalkhali M, Aram‎S, Zarrabi H, Kafie M, Heidarzadeh A. ‎ Lamotrigine Augmentation versus Placebo in Serotonin ‎Reuptake Inhibitors-‎Resistant Obsessive-Compulsive Disorder: ‎A Randomized Controlled Trial. Iran J Psychiatry. 2016;11(2):104-114.